RT Journal Article SR Electronic T1 Rapid fluoroquinolone resistance detection in Pseudomonas aeruginosa using mismatch amplification mutation assay-based real-time PCR JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.12.12.21266792 DO 10.1101/2021.12.12.21266792 A1 Danielle E. Madden A1 Kate L. McCarthy A1 Scott C. Bell A1 Olusola Olagoke A1 Timothy Baird A1 Jane Neill A1 Kay A. Ramsay A1 Timothy J. Kidd A1 Adam G. Stewart A1 Shradha Subedi A1 Keat Choong A1 Tamieka A. Fraser A1 Derek S. Sarovich A1 Erin P. Price YR 2022 UL http://medrxiv.org/content/early/2022/01/01/2021.12.12.21266792.abstract AB Background Antimicrobial resistance (AMR) is an ever-increasing global health concern. One crucial facet in tackling the AMR epidemic is earlier and more accurate AMR diagnosis, particularly in the dangerous and highly multi-drug resistant ESKAPE pathogen, Pseudomonas aeruginosa.Objectives We aimed to develop two SYBR Green-based mismatch amplification mutation assays (SYBR-MAMAs) targeting GyrA T83I (gyrA248), and GyrA D87N, D87Y, and D87H (gyrA259). Together, these variants cause the majority of fluoroquinolone (FQ) AMR in P. aeruginosa.Methods Following assay validation, the gyrA248 and gyrA259 SYBR-MAMAs were tested on 84 clinical P. aeruginosa isolates from Queensland, Australia, 45 of which demonstrated intermediate/full ciprofloxacin resistance according to antimicrobial susceptibility testing.Results Our two SYBR-MAMAs correctly predicted an AMR phenotype in the majority (84%) of isolates with intermediate/full FQ resistance. Importantly, all FQ-sensitive strains were predicted to have a sensitive phenotype. Whole-genome sequencing confirmed 100% concordance with SYBR-MAMA genotypes.Conclusions Our GyrA SYBR-MAMAs provide a rapid and cost-effective method for same-day identification of FQ AMR in P. aeruginosa. An additional SYBR-MAMA targeting the GyrB S466Y/S466F variants would increase FQ AMR prediction to 91%. Clinical implementation of our assays will permit more timely treatment alterations in cases where decreased FQ susceptibility is identified, leading to improved patient outcomes and antimicrobial stewardship.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Advance Queensland (awards AQIRF0362018 and AQRF13016-17RD2), an Australian Government Research Training Program Scholarship, the Wishlist Sunshine Coast Health Foundation (award 2019-14), and the National Health and Medical Research Council (award 455919). The funders had no role in study design, data acquisition, analysis, interpretation, writing or submission of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sample collection and analysis was approved by The Prince Charles Hospital Human Research Ethics Committee or the Royal Brisbane and Womens Hospital Institutional Review Board. All CF and COPD participants provided written consent (Webb et al., 2021 doi: 10.1101/2021.08.30.21262864). A waiver of informed consent was approved for other sample types due to a low-to-negligible risk assessment (McCarthy & Paterson, 2017 PMID: 28089143; Stewart et al., 2021 PMID: 33781999).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genome sequence data generated in this study are available from NCBI BioProject PRJNA761496.